PARP inhibitor · small molecule
pamiparib
1 active trials across 3 of our biomarkers, targeting PARP. Not approved for any biomarker on marked.bio yet.
Also known as BGB-290.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| IDH1/2 mutation | 1 | 2 | Phase 1 |
| BRCA1/2 mutation | 0 | 9 | – |
| MSI-H / dMMR | 0 | 1 | – |
Trials
1 of 11 trials shown
-
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
pamiparibtemozolomide
…ave histologically confirmed World Health Organization (WHO) grade III-IV newly diagnosed IDH1/2-mutant glioma.
IDH1/2 mutationGlioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma
-
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation
Have a deleterious mutation in BRCA1/2 , or HRD score ≥ 9.
BRCA1/2 mutationMetastatic Castration-resistant Prostate Cancer
-
A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects
Cohort B - a pathogenic germline BRCA1 or BRCA2 mutation Note: Genomic features associated with HRD must have been determined from a sample obtain…
BRCA1/2 mutationCancer
-
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
pamiparibtemozolomide
Patients must have IDH1/2-mutant glioma.
IDH1/2 mutationIDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma
-
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
…d by histological diagnosis and immunohistochemistry (IHC) and with a germline or somatic BRCA1/2 mutation:
BRCA1/2 mutationOvarian Cancer, Carcinosarcoma
-
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
…fferentiation with HRD deficiency by CTC-HRD assay and/or deleterious germline or somatic mutation in BRCA1 or BRCA2
BRCA1/2 mutationMetastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD)
-
Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
Confirmed deleterious or suspected deleterious germline BRCA1 or BRCA2 mutation
BRCA1/2 mutationHER2-negative Breast Cancer
-
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
…rian cancer (including fallopian cancer or primary peritoneal cancer), harboring germline BRCA1/2 mutation 4.
BRCA1/2 mutationAdvanced High-grade Ovarian Cancer, Triple Negative Breast Cancer
-
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
A deleterious BRCA1 or BRCA2 mutation (germline or somatic)
BRCA1/2 mutationAdvanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
-
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
pamiparibtemozolomide
Participants with homologous recombination deficiency (HRD+) or known BRCA mutant ovarian cancer Previously received at least one line of platinum-containing therapy in th…
BRCA1/2 mutationLocally Advanced or Metastatic Solid Tumors
-
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
…rious or suspected deleterious germline or somatic breast cancer susceptibility gene 1/2 (BRCA1/2) mutations or with homologous recombination deficiency (HRD).
BRCA1/2 mutationMSI-H / dMMRSolid Tumors
No trials match these filters.